Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide
- 19 March 2004
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 60 (2), 109-114
- https://doi.org/10.1007/s00228-004-0746-z
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.2003
- Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.Drug Metabolism and Disposition, 2002
- Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human HepatocytesThe Journal of pharmacology and experimental therapeutics, 2002
- Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transportersClinical Pharmacology & Therapeutics, 2002
- Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.2001
- Rifampin decreases the plasma concentrations and effects of repaglinideClinical Pharmacology & Therapeutics, 2000
- Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?International Journal of Obesity, 2000
- Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction.1999
- Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.JCI Insight, 1992
- The increase in urinary excretion of 6 beta‐hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.British Journal of Clinical Pharmacology, 1989